Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Research & Development (2020 - 2023)

Candel Therapeutics' Research & Development history spans 4 years, with the latest figure at -$9.3 million for Q4 2023.

  • For Q4 2023, Research & Development fell 287.21% year-over-year to -$9.3 million; the TTM value through Dec 2023 reached $7.9 million, down 61.8%, while the annual FY2024 figure was $19.3 million, 143.25% up from the prior year.
  • Research & Development for Q4 2023 was -$9.3 million at Candel Therapeutics, down from $5.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.9 million in Q2 2023 and bottomed at -$9.3 million in Q4 2023.
  • The 4-year median for Research & Development is $5.0 million (2022), against an average of $3.5 million.
  • The largest annual shift saw Research & Development surged 96.77% in 2022 before it plummeted 287.21% in 2023.
  • A 4-year view of Research & Development shows it stood at $3.5 million in 2020, then grew by 9.05% to $3.9 million in 2021, then increased by 29.01% to $5.0 million in 2022, then tumbled by 287.21% to -$9.3 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Research & Development are -$9.3 million (Q4 2023), $5.8 million (Q3 2023), and $5.9 million (Q2 2023).